News

Explore the top dermatology news of 2024, highlighting breakthroughs, innovations, and key clinical insights shaping the future of skin care and treatment.

Catch up on Dermatology Times conference coverage from January through June of this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in atopic dermatitis this year.

Catch up on coverage of FDA-approved drugs in the first half of 2024.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in aesthetic/cosmetic dermatology this year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Deucravacitinib achieved ACR20 response in patients with PsA at week 16, with a safety profile consistent with previous studies.

Dermatology Times is looking back on the top dermatology news headlines from 2024.

At the inaugural Horizons in Advanced Practice meeting, Dr. Noor highlighted the value of amplifying the voices of physician assistants and nurse practitioners to advance patient care.

Hidradenitis suppurativa requires clinical vigilance, empathy, and the courage to escalate therapy early.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in prurigo nodularis this year.

Dermatology Times is looking back on the top stories in dermatology that involve strides in skin health equity: addressing disparities for skin of color, women, LGBTQ+ patients, and improving care access.

These promising results align with what was discovered in the single-ascending dose portion of the trial earlier this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in rosacea this year.

Messina, senior VP of Aesthetics R&D at Allergan Aesthetics, highlights key trends shaping the aesthetic medicine landscape in 2025.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in chronic hand eczema this year.

In case you missed it, this week we had news about tapinarof’s FDA approval in AD patients 2 and older, new ICD-10 codes for CCCA and FFA, a phase 2 study of INF904, and more.

Renata Block, MMS, PA-C; Ted Lain, MD, MBA, FAAD; Zoe Diana Draelos, MD; and Cheri Frey, MD, FAAD, bust common skin care myths in a Dermatology Times custom video series.

Dermatology Times is looking back on the top stories in dermatology from the month of December.

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.

Trust and transparency are key in physician wealth management, according to David Mandell, JD, MBA.

Dermatology Times is recapping our top expert interviews from the month of December.

Follow-up phase 3 data showed BF-200 ALA to be a safe and effective therapy for AK, when compared to placebo.

Experts in the field shared insights with Dermatology Times on what they found most innovative, educational, and helpful in the past year.

The "whole body" study at Northwestern will be lead by Amy Paller, MD, begins soon.

In this month’s Cosmetic Conundrums column, learn how radiant, luminous skin can be achieved with cosmeceuticals.

With the right strategies and a clear vision, retirement can unfold as a rewarding chapter.

Itisha S. Jefferson, a patient advocate and medical student, discusses the significance of new ICD-10 codes for CCCA and FFA, improving diagnosis and care.

The new research identified notable improvements in disease severity, sweat reduction, and quality of life for patients treated with sofpironium.